Mind Medicine Australia Webinar - Four

Webinar: Psychiatry and Psychedelics

Join this free, 60-minute online webinar to gain access to insights and learn about ground breaking treatments to chronic mental health conditions.

There is a lot of positive discussion currently about the possibilities of treating psychiatric patients with psychedelic-assisted psychotherapy.

But how well will the discipline of psychiatry adapt to the current psychedelic narrative and what changes in attitudes and processes will psychiatry have to make to accept psychedelic medicines as part of its therapeutic armamentarium?

Remember too that the use of psychedelics in psychiatry went wrong once before. How can we make sure this doesn’t happen again?

These and other questions about the merging of these two great narratives will be discussed by Dr Nigel Strauss in this webinar.

A link will be emailed to you with the viewing details once you have registered.

Following the presentation there will be a Q&A panel with Dr Nigel Strauss. This will be an opportunity to engage in a discussion about psychedelic-assisted psychotherapies for mental illness broadly, and what Mind Medicine Australia and other local organisations are doing here in Australia.

More about medicinal psychedelic treatments:

Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.

The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.